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Abstract: Human serum albumin (HSA) is the most abundant carrier protein in the human
body. Competition for the same binding site between different ligands can lead to an increased
active concentration or a faster elimination of one or both ligands. Indomethacin and quercetin
both bind to the binding site located in the IIA subdomain. To determine the nature of the
HSA-indomethacin-quercetin interactions, spectrofluorometric, docking, molecular dynamics studies,
and quantum chemical calculations were performed. The results show that the indomethacin and
quercetin binding sites do not overlap. Moreover, the presence of quercetin does not influence the
binding constant and position of indomethacin in the pocket. However, binding of quercetin is
much more favorable in the presence of indomethacin, with its position and interactions with HSA
significantly changed. These results provide a new insight into drug-drug interactions, which can
be important in situations when displacement from HSA or other proteins is undesirable or even
desirable. This principle could also be used to deliberately prolong or shorten the xenobiotics’ half-life
in the body, depending on the desired outcomes.
Keywords: human serum albumin; quercetin; indomethacin; pharmacokinetic interactions;
fluorescence spectroscopy; docking; molecular dynamics; quantum chemistry
1. Introduction
Human serum albumin (HSA) is the most abundant protein in human plasma (60%, w/w) [1]. It is
a 585-residue monomeric protein comprised of three homologous domains (I–III), each of which is
composed of two subdomains (A and B) [2]. Its primary role in the body is preserving the oncotic
pressure, but it also has additional functions, such as plasma pH regulation and transfer and storage of
small hydrophobic molecules [3]. Two binding sites, where a majority of the ligands bind, are located
in subdomains IIA and IIIA, and are also called warfarin and benzodiazepine sites, respectively [4].
The binding site located in the subdomain IIA appears to be the most prominent one and can
accommodate structurally different ligands [5,6].
Various exogenous compounds bind to the IIA HSA subdomain, including drugs (e.g.,
indomethacin [5]), as well as flavonoids [7,8]. Flavonoids are a group of phenolic compounds,
highly abundant in fruits and vegetables [9,10]. Apart from their antioxidative properties, which are
the best described [11], they also have a significant role in preventing cardiovascular diseases [12–14].
Binding of flavonoids to HSA has been extensively studied using various techniques, such as
fluorescence spectroscopy [7,8,15–17], circular dichroism [17–20], and molecular modeling [17–21],
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usually combining more than one approach. Since many different compounds bind in the IIA
subdomain of HSA, there exists a possibility of their mutual competition for the binding sites and
thus the potential displacement of either one or both ligands [22], in which the flavonoids can also
participate [23]. However, there are several prerequisites that need to be met (e.g., kidney or liver
diseases) for this type of interaction to have clinically important consequences [24–26]. On the other
hand, to the best of our knowledge, a situation where one ligand increases the binding affinity of
another ligand for HSA has not yet been reported in the literature, but could have important and even
useful consequences. One such example is presented in this research.
We have investigated the interaction nature of indomethacin (IND), a well-known
anti-inflammatory drug, and quercetin (QUE), one of the most abundant flavonoids in human
nutrition, in binding to the binding site located in the IIA HSA domain. For this, we have combined
experimental fluorometric experiments with docking, molecular dynamics simulations, and quantum
chemical calculations. Binding of ligands in the IIA subdomain can easily be monitored by measuring
the fluorescence intensity of the Trp214 residue and from the observed change in fluorescence their
binding constants also can be calculated [27]. An alternative way to measure the binding of QUE to
HSA is based on the fact that, when it is unbound in solution, QUE fluorescence is negligible, but when
it is bound to HSA, its fluorescence increases dramatically. In this way both the binding of QUE to
HSA and its dissociation from HSA caused by displacement can be observed [7,28,29]. The structures
of QUE and IND are shown in Figure 1.
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2. Results and Discussion
2.1. Simultaneous Binding of Indomethacin and Quercetin to HSA
For determination of the IND and QUE binding constants, Formulae 1–3 were used, as is explained
in the Experimental section. Both IND and QUE bind in the vicinity of the Trp214 residue in the
subdomain IIA [5,29], and their binding constants were determined to be (1.73 ± 0.64) × 105 and
(1.44 ± 0.05) × 105 mol−1 dm3, respectively. To evaluate the risk of drug-drug interactions while
binding to HSA, in vitro techniques have been used for a long time [22,30,31]. Results obtained in this
way cannot be directly extrapolated to physiological conditions but can provide valuable insights [32].
In this interaction study, QUE fluorescence was used. QUE has a 5-OH group, which is known to
quench its intrinsic fluorescence [28]. However, when it is bound to HSA, quercetin fluoresces at
excitation and emission wavelengths of 450 and 500–540 nm, respectively. If quercetin is unable to
bind to HSA or its binding affinity is changed due to an external factor, this can be observed from
the intensity of their maximum fluorescence (Fmax) and the concentration needed to achieve it (cmax).
Using the obtained IND binding constant and Formulae 4–5, it is possible to determine the IND
concentration needed to saturate a certain fraction of the HSA binding sites, with a presumed 1:1
binding ratio.
After incubation with different concentrations of IND, QUE concentration was gradually increased
until Fmax was achieved (Figure 2). The presence of IND significantly increased the QUE’s Fmax (by
approximately 20%) and decreased its cmax from approximately 55 µM to 25 µM (i.e., by approximately
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65%). These results indicate that IND and QUE do not bind in the same location within the HSA
IIA subdomain. Moreover, the presence of IND significantly increases QUE’s binding constant
through formation of a ternary HSA-IND-QUE complex. Additionally, the decrease in fluorescence
intensity after reaching Fmax can be explained by the inner filter effect, which plays a significant
role in the ligand concentrations used in these experiments [33]. Alongside an increasing quercetin
concentration, the indomethacin concentration needed to saturate the HSA follows a typical saturation
curve: the higher the HSA saturation already is, a higher increase in indomethacin concentration is
needed to change the saturation for a given percentage (for an HSA saturation of 22%, 38%, 63%,
and 92% the corresponding indomethacin concentrations are 2.95, 5.82, 13.63, and 72.02 µM). This inner
filter effect is clearly visible at a quercetin concentration of 120 µM, where its fluorescence decreases
with an increase in indomethacin concentration. Additionally, at these high concentrations, contact
quenching can also contribute to a fluorescence decrease, but at lower concentrations its effect is less
pronounced. The obtained results are in accordance with results obtained by Zsila et al. [18] and
Dufour and Dangles [7], as well as with the crystallographic structures obtained by Petitpas et al. [34]
and Yamasaki et al. [35,36], stating that the binding site in the subdomain IIA of HSA is large enough
to accommodate multiple ligands at the same time. This was also confirmed for the case of interactions
between warfarin and quercetin [29]. The difference in QUE fluorescence is likely brought about
either by (i) conformational changes within the ligand; (ii) potential changes in the size and shape
of the IIA binding site caused by the presence of IND; or (iii) through the direct interaction of IND
and QUE, which decreases QUE’s rotational and translational freedom and consequently stabilizes
the ternary HSA-IND-QUE complex. In what follows, our computational analysis clearly shows that
changes in the QUE fluorescence occur as a result of its modified interactions with the protein: in the
presence of IND, QUE enters deeper into the HSA binding pocket and its binding energy is significantly
enhanced, which likely restricts its conformational freedom, even at the expense of an unfavorable
mutual interaction with IND.
Figure 2. Dependence of quercetin fluorescence (λem = 526 nm) on indomethacin concentration.
2.2. Molecular Modeling of the Binary and Ternary HSA Complexes
To further investigate the IND-QUE interactions in binding to HSA, docking and molecular
dynamics (MD) simulations were conducted. First, docking of quercetin to a crystallographic structure
of HSA (PDB entry 2BXM) [5] was performed to see the difference in QUE binding in the presence and
absence of IND, but also to obtain the initial quercetin and indomethacin poses for the MD simulations.
Four different quercetin species were docked, two anions and two fluorescent dianion species (Figure 3),
which were found to be most abundant according to Dangles et al. [37].
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Docking results of the QUE anion at Position 7 can be seen in Figure 4. QUE’s (blue) negatively
charged 7-oxo group is located next to the IND’s (yellow) carboxylate moiety, suggesting an interaction
between them. Since the results for all other quercetin species were virtually identical, the MD
calculations were performed only for the quercetin anion at Position 7, as it is physiologically the
most prevalent QUE protonation form at a pH of 7.4, with a determined pKa = 6.4 [38]. In addition,
indomethacin was considered as a monoanionic system having a deprotonated carboxylic group, in
line with its experimental pKa = 4.3 [39]. The MD simulations were conducted for both the binary
complexes (HSA-IND and HSA-QUE), as well as for the ternary HSA-IND-QUE complex. The results
show that there is no significant difference in the IND position between the binary HSA-IND complex
(IND is depicted in pink and HSA in brown) and the ternary HSA-IND-QUE complex (IND is depicted
in yellow and HSA in light blue) (Figure 5). The same can be said for HSA, with an exception of a
slight loss of tertiary structure in one of the α helices.
Figure 4. Quercetin anion at Position 7 (blue) docked to a crysta lographic structure of indomethacin
(ye low) bound to SA. The Tr r i i i
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Figure 5. Indomethacin and HSA conformations before (indomethacin is depicted in pink and HSA
in brown) and after (indomethacin is depicted in yellow and HSA in light blue) quercetin binding
(quercetin is not shown), with the Trp214 shown.
On the other hand, the presence of IND greatly influences QUE’s binding pose. As can be seen
from Figure 6, in the absence of IND, QUE is located at the entrance of the IIA subdomain, but in its
presence, QUE is positioned much deeper inside the hydrophobic pocket. This can explain QUE’s
higher fluorescence intensity, as it is known that both the hydrophobic environment and the restriction
of the intramolecular motion can cause an enhanced fluorescence intensity, as the energy cannot
dissipate through other means [40,41].
Figure 6. Quercetin poses and HSA conformation in the absence (quercetin is depicted in purple and
HSA in brown) and in the presence of indomethacin (quercetin is depicted in blue, HSA in light blue,
and indomethacin in yellow), with the Trp214 shown.
Molecular Mechanics Generalized Born Surface Area (MM-GBSA) analysis of the MD trajectories
(Table 1) confirms that the presence of IND changes both the affinity of the HSA towards QUE and
the position of the latter ligand within the binding site, which explains the observed changes in the
fluorescence spectra reported earlier. Specifically, the calculated QUE’s binding free energy in the
binary HSA-QUE complex is ∆Gbind = −20.0 kcal mol−1, which is increased to −30.4 kcal mol−1 in
IND’s presence. We note that both of these ∆Gbind values are likely overestimated in absolute terms,
which is a known limitation of the MM-GBSA approach, as extensively discussed in a recent review by
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Homeyer and Gohlke [42]. However, these authors also underlined its huge potential in predicting
the relative binding energies in the biomolecular complexes. Therefore, in this context, these values
evidently show that IND promotes the HSA-QUE interactions. With this in mind, our next task
was to inspect how much of the mentioned 10.4 kcal mol−1 increase in the binding affinity can be
attributed to the mutual interaction between QUE and IND themselves, and whether this represents
the driving force for the change in the QUE position within the active site. To do so, we selected a
representative structure of the ternary HSA-IND-QUE complex and extracted the geometry of the
interacting ligands from the active site. These were kept frozen and submitted to DFT calculations
at the M06–2X/6–31+G(d,p) level of theory, which gave a positive interaction free energy among the
ligands of ∆Gint = +4.2 kcal mol−1. The latter indicates no favorable pairing between QUE and IND
themselves in the ternary complex, leading to the conclusion that an increase in QUE binding in the
presence of IND predominantly originates from the modified interactions with the protein. QUE’s
orientation relative to the location of the indomethacin moiety and the most important amino acid
residues contributing to quercetin binding are shown in Figure 7a. As can be seen, QUE’s relative
position in the absence (purple) and in the presence (dark blue) of IND (yellow) significantly differs
and the amino acids contributing the most to its binding are located at the opposite side of the binding
pocket. In Figure 7b, the HSA conformational change can be observed, with an emphasis on the top
three contributing residues (Lys195, Ser454, and Asn458). At this point it is important to delineate
the two different effects exerted by the presence of IND: (1) it increases the HSA binding affinity for
QUE; and (2) it results in a changed QUE fluorescence spectrum. Our analysis suggests that, while the
former effect has no direct favorable contribution from the QUE-IND interactions themselves, the latter
is brought about by a changed QUE environment in the ternary complex that has joint contributions
from the vicinity of the IND and changed HSA residues.
Table 1. Contribution of the top individual residues to the binding of quercetin to HSA in the absence
and in the presence of indomethacin obtained with the MM-GBSA approach. All values are in kcal
mol–1 (# means number).
HSA-Quercetin Complex HSA-Indomethacin-Quercetin Complex
Residue Name Residue # Contribution to ∆Gbind Residue Name Residue # Contribution to ∆Gbind
Ser 342 −2.70 Asn 458 −4.17
Arg 218 −2.69 Lys 195 −1.88
Val 343 −2.50 Ser 454 −1.85
Pro 447 −1.09 Val 455 −1.68
Trp 214 −0.63 Tyr 452 −1.59
Lys 195 −0.60 Ala 194 −1.25
Ser 192 −0.53 Leu 198 −0.80
Gln 196 −0.33 Asp 451 −0.77
Glu 450 −0.32 Ala 191 −0.48
Met 446 −0.23 Glu 188 −0.48
Total ∆Gbind (Quercetin) −20.0 Total ∆Gbind (Quercetin) −30.4
Moreover, a decomposition of the calculated ∆Gbind values into contributions from individual
residues clearly indicates different binding poses for QUE. Specifically, without IND, QUE binding
is dominated by Ser342, Arg218, and Val343, whose contributions between −2.7 and −2.5 kcal mol−1
account for around 40% of the total binding free energy. Together with the remaining seven residues
indicated in Table 1, they are responsible for around 60% of the binding. Interestingly, none of these
10 residues are governing QUE-HSA binding when IND is present, thus confirming a change in the
binding position. The only exception is provided by Lys195, which increases its contribution from
−0.60 to −1.88 kcal mol−1 in the presence of IND. This comes as a result of the fact that, without
IND, Lys195 uses its side-chain protonated amino group (−NH3+) to form cation·pi interactions with
the benzopyran-4-one fragment on QUE, while, when IND is present, these are replaced by a more
favorable hydrogen bonding with the 3′- and 4′-hydroxyl groups on the phenyl ring, which results in
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an around three times increase in the Lys195 contribution. It is also interesting to observe that, without
IND, QUE is positioned to strongly interact with Arg218 through favorable cation···pi interactions,
which amount to over 10% of the total binding energy. Yet, when IND is present, this interaction is
replaced by hydrogen bonding to the backbone amide of the same Arg218, but without a significant
contribution to the binding free energy in that case (Table 1), thus again confirming a change in the
binding pose.
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indomethacin (yellow) with three ami o acids contributing the most to its binding. (a) Comparison
of the relative quercetin locations in the absence and in the presence of indomethacin; (b) local
changes in HSA conformation between a binary HSA-indomethacin complex (HSA depicted in brown,
indomethacin is not shown) and a ternary HSA-indomethacin–quercetin complex (HSA is depicted in
light blue, quercetin in dark blue, and indomethacin is not shown).
Next, we note in passing that in the binary HSA-QUE complex, individual residue contributions
are more equally distributed between the top contributors, whereas in the ternary HSA-IND-QUE
complex, there is a large contribution of a single residue, Asn458, which exceeds 4 kcal mol−1. The latter
is brought about by persistent hydrogen bonding between its amide N–H side chain and the anionic
deprotonated phenoxide at Position 7 in QUE, with an average O(QUE)···H–N(Asn458) value of 2.55 Å
during the entire simulation. Nevertheless, despite this stable hydrogen bond, the overall number
of hydrogen bonds that QUE establishes with all the binding site residues is decreased from 0.6 per
ns when QUE is bound alone to 0.5 per ns when both ligands are present. This is consistent with the
observed higher fluorescence of the ternary complex; QUE located deeper in the hydrophobic binding
site is more rigid, which is accompanied by a slightly lower ability to create hydrogen bonds, which
then results in the different spectroscopic responses demonstrated here.
Lastly, let us also mention that an analogous analysis of the IND binding (Table S1) shows that,
on its own, IND is a much stronger HSA binder than QUE (∆Gbind = −33.5 kcal mol−1), thus nicely
reproducing a trend in the experimentally measured binding constants, and that this value is only
moderately increased to−38.7 kcal mol−1 when QUE is present, thus tying in with the already presented
conclusions. Decomposition of both of the mentioned binding energies into contributing residues
reveals the repetition of many of them among the top contributors, therefore confirming similar binding
poses for IND in both the secondary and ternary complexes. In addition, analysis of both Table 1 and
Table S1 clearly indicates the significance of Trp214 in the binding of both ligands, which agrees with
the experimental observations presented earlier.
Having all of these results at hand, the following conclusion can be made: IND is a stronger
binder of the two, and it binds to HSA at its most favorable position, irrespective of the QUE presence.
On the other hand, when alone, QUE binding is also favorable, but it is not maximized, as QUE binds
in a shallower HSA region. The likely reason is that IND binding deepens the HSA binding site (by
rearranging the conformations of residues in the vicinity of Lys195) (Figure 7b). This then allows QUE
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to enter deeper into the binding pocket and increase its binding affinity—a process QUE seems to be
unable to undertake in the parent binding site—even at the expense of being unfavorably located in the
close vicinity of IND. This kind of behavior changes in the secondary and tertiary HSA structure, as has
already been observed for other ligands [43]. The next step in studying the HSA-IND-QUE interactions
would be to perform so-called cluster-continuum calculations with individual amino acid residues
(especially Lys195), to elucidate their individual contributions, as was done by Cappelli et al. [44] and
Rybicka et al. [45].
3. Materials and Methods
Quercetin (purity ≥ 99%) and fatty acid-free HSA (purity ≥ 96%) were purchased from
Sigma-Aldrich (St. Louis, MO, USA) and indomethacin (purity ≥ 99%) was purchased from Acros
Organics, (Geel, Belgium). All chemicals were used without further purification. Binding of quercetin
and indomethacin to HSA was studied using spectrofluorimetry, molecular docking, and molecular
dynamics simulations.
3.1. Fluorescence Spectroscopy
HSA solutions were made daily before measurements in Dulbecco phosphate-buffered saline (PBS)
(137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.47 mM KH2PO4) [46]. Quercetin and indomethacin
were dissolved in DMSO:PBS 1:1 and HSA was dissolved in PBS. In all experiments, the concentration
of DMSO was held below 4%. This was done to prevent the conformational changes in HSA due
to changes in the solvent dielectric constant. Steady-state fluorescence spectra were recorded using
an OLIS RSM 1000F spectrofluorometer (Olis Inc., Bogart, GA, USA) equipped with a thermostated
cell holder at 25 ◦C. Hellma Analytics 105.253-QS fluorescence cells with a light path of 10 × 2 mm
(excitation × emission) were used. The excitation wavelength was 295 nm (tryptophan absorption
maximum) and the emission spectra were recorded in the range 310–370 nm, where only HSA has
fluorescent properties, with the observed maximum at 340 nm. All studies were performed in duplicate
at 25 ◦C using 1.24 mm excitation and emission slit widths. All solutions were analyzed after 2 h
incubation period.
For the binding constant determination, the HSA concentration was held constant at 1 µM while
the ligand concentration varied between 0.03 and 10 µM and the effect of the DMSO as a co-solvent
was annulated by adding a small aliquot of DMSO to a pure HSA solution. At the studied wavelength
range both the HSA and quercetin absorb light. Based on the molar absorbance coefficients at 295 and
340 nm, and due to the relatively high concentrations, the inner filter effect cannot be neglected [47].




where Aex = ε295 × c × l is the absorbance at the excitation wavelength (c is ligand concentration and l
= 1 cm) and Aem = ε340 × c × l is the absorbance at the emission wavelength (l = 0.2 cm).
Each spectrum obtained during titration is an average of 10,000 fluorescence spectra measured in
10 s. Equilibrium constants were calculated by a global fit at all wavelengths with SPECFIT [48–51]
software. A single, significant, and spectrally active species was suggested by the singular value
decomposition analysis and was attributed to the known spectrum of the HSA. This analysis also
suggested a 1-to-1 complex formation and did not indicate any higher order complexes. Therefore,
the proposed binding model is given by Equations (2) and (3), where K is the association constant of
the complex:
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The association constant values calculated from fluorescence titrations for the suggested
HSA–ligand complexes are given in mol−1 dm3. Higher values of K indicate stronger binding
and higher complex stability.
For the HSA-IND-QUE interactions, the HSA concentration was kept at 6 µM while the fraction
of HSA saturated by indomethacin varied: 0%, 22%, 38%, 63%, and 92%. The saturated fraction was









where K is the binding constant, [cL] is the concentration of the HSA-ligand complex, [cf] is the
concentration of the unbound HSA, [L] is the free ligand concentration, [c] is the total HSA concentration,
and p is the fraction of saturated HSA. Flavonoid binding measurements were conducted at an excitation
wavelength of 450 nm to maximize the fluorescence of the bound flavonoid, and the emission was
recorded in the 466–580 nm range, with a maximum at 526 nm. Competition of indomethacin and
quercetin for binding to HSA was determined based on the maximum intensity of fluorescence (Fmax)
of quercetin and the concentration needed to achieve it (cmax), as was done previously [29].
3.2. Docking Studies
Docking studies were performed using AutoDock 4.2.6. (The Scripps Research Institute, La Jolla,
CA, USA) [52], which uses dispersion, hydrogen bonds, electrostatic, and desolvation components
for the determination of the most probable complex conformation. This program was used to obtain
the initial binding poses of quercetin to HSA in the presence and in the absence of the indomethacin
molecule. 3D coordinates of the HSA–indomethacin complex were taken from the RCSB Protein Data
Bank (entry 2BXM) [5] and missing side chains were added. Additionally, water molecules were
omitted from the structure, hydrogen atoms were introduced where necessary, and all Lys and Arg
side chains were protonated, while all Asp and Glu side chains were deprotonated. Both the amino
and carboxyl ends were charged, His242 was protonated at the Nε position, while all other His side
chains were protonated at the Nδ position, based on visual inspection. This resulted in a total charge
of the HSA molecule of −14. The initial 3D quercetin conformation was determined using HyperChem
8.0 (Hypercube, Inc., Gainesville, FL, USA), and its charge was set to the most abundant anionic and
fluorescent anion species at pH 7.4, taken from Dangles et al. [37]. The quercetin partial charges
were calculated according to Ionescu et al. [53]. A grid map of size 80 × 80 × 80 Å was generated
with a 0.375 Å spacing centered on the coordinates of the side-chain nitrogen in Trp214 in Sudlow’s
site I in subdomain IIA by the AutoGrid program [52], and then the Lamarckian genetic algorithm
(LGA) [54] was applied. The receptor molecule was regarded as rigid while all ligand single bonds
could rotate freely during the Monte Carlo simulated annealing procedure. Ligand flexible docking
simulations were performed with 100 runs, a population size of 150, 2.5 × 107 energy evaluations,
27,000 was the number of generations, a rate of gene mutation of 0.02, and a rate of crossover of 0.08.
The root-mean-square-deviation (RMSD) of 2.0 Å was used as a criterion for cluster analysis of the
docking results (in order to determine if the two docked conformations were similar enough to be
included in the same cluster). Verification and modification of the crystallographic structure, as well as
the results visualization, and interpretation were conducted using UCSF Chimera 1.10.1. (University
of California, San Francisco, CA, USA) [55].
3.3. Molecular Dynamics Simulations and Quantum Chemical Calculations
The starting point of the molecular dynamics (MD) simulations were structures obtained by the
docking procedure described above involving the QUE molecule bound to the crystallographic structure
of the HSA-IND complex. To parameterize the QUE and IND molecules, geometry optimization
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and RESP charge calculations were performed using the Gaussian 16 program at the HF/6–31G(d)
level to be consistent with the employed GAFF force field, while the protein was modeled using the
AMBER ff14SB force field. In total, three HSA complexes were prepared (HSA-IND, HSA-QUE, and
HSA-IND-QUE). Such complexes were then solvated in a truncated octahedral box of TIP3P water
molecules spanning a 20 Å-thick buffer, neutralized by an equivalent of Na+ ions and submitted to
geometry optimization in the AMBER16 program [56], employing periodic boundary conditions in
all directions. Optimized systems were gradually heated from 0 to 300 K and equilibrated during
30 ps using NVT conditions, followed by productive and unconstrained MD simulations of 300 ns,
employing a time step of 2 fs at a constant pressure (1 atm) and temperature (300 K), the latter held
constant using a Langevin thermostat with a collision frequency of 1 ps−1. Bonds involving hydrogen
atoms were constrained using the SHAKE algorithm [57], while the long-range electrostatic interactions
were calculated employing the Particle Mesh Ewald method [58]. The nonbonded interactions were
truncated at 10.0 Å. The binding free energies, ∆Gbind, of QUE and IND within the IIA binding pocket of
HSA were calculated using the established MM-GBSA protocol [59,60] available in AmberTools16 [56],
and in line with our earlier reports [61,62]. MM-GBSA is a widely used method for binding free
energy calculations from snapshots of the MD trajectory with an estimated standard error of 1–3 kcal
mol−1 [59]. For that purpose, 1000 snapshots collected from the last 30 ns of the corresponding MD
trajectories were utilized. The calculated MM-GBSA binding free energies were decomposed into a
specific residue contribution on a per-residue basis according to the established procedure [63,64].
This protocol calculates contributions to ∆Gbind arising from each amino acid residue and identifies the
nature of the energy change in terms of the interaction and solvation energies or entropic contributions.
Lastly, in order to evaluate a mutual interaction between the QUE and IND themselves in the ternary
HSA-IND-QUE complex, a frozen geometry of both ligands, extracted from the representative structure
of the complex during MD simulations, was submitted to M06–2X/6–31+G(d,p) calculations. To account
for the effect of the enzyme environment, we included the implicit CPCM solvent model, taking the
dielectric constant of ε = 4 and all other parameters for pure water, as employed in many of our
studies concerning various aspects of biomolecular systems [61,65,66]. The final interaction energy was
calculated by comparing the so-obtained energy with energies of individual ligands, again frozen in
the geometry they assume in the complex and considering only electronic energy contribution without
thermal corrections.
4. Conclusions
Even though they both bind to the IIA subdomain of HSA, indomethacin and quercetin interact
with different parts of the binding site. Additionally, binding of quercetin has little influence on
the indomethacin affinity, while the presence of indomethacin significantly increases quercetin’s
binding constant. This can be seen through the increase of quercetin’s fluorescence intensity (Fmax)
and the decrease in its concentration needed to achieve it (cmax). In the absence of indomethacin,
quercetin binds at the entrance of the IIA binding site, but the presence of indomethacin changes the
conformations of the amino acid residues inside the binding site. This allows quercetin to bind deeper
into the binding pocket, without changing the indomethacin conformation. Even though this new
quercetin conformation results in a stronger binding to HSA, quercetin is unable to perform this HSA
conformational change on its own, due to its weaker binding constant compared to indomethacin.
Apart from the regular, competitive displacement interactions and non-interactions (e.g.,
warfarin-quercetin [29]), the obtained insight into the binding process suggests a third option for
ligand-ligand interactions in a simultaneous binding to the same protein binding site, where one
ligand increases the binding constant of the other ligand. At this moment, we are not aware of other
studies that have reported similar results, which could have important consequences for the fate of
xenobiotics inside the body. In most cases, pharmacokinetic interactions involving displacement of
xenobiotics from their carrier proteins is undesirable as it can lead to their higher active concentrations
and potential adverse effects, or faster elimination and reduced efficiency (e.g., in cases of antibiotics
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which have time-dependent effectiveness [6]). However, in certain cases, displacement of xenobiotics
is desirable, as it reduces their toxicity (e.g., displacement of ochratoxin [67] or aflatoxin B1 [68] from
HSA). In this regard, knowing to which one of the three possible types of ligand-ligand interactions our
xenobiotic is subject to, can be of great importance in optimizing its desirable effects and preventing its
undesirable effects, such as deliberately prolonging or shortening the xenobiotic half-life.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/16/
5740/s1. Table S1. Contribution of top individual residues to the binding of indomethacin to HSA in the absence
and in presence of quercetin obtained with the MM-GBSA approach. All values are in kcal mol−1.
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